Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. provided an overview of Kintara's and TuHURA's recent corporate and clinical advancements and outlined upcoming expected near term milestones. In April 2024, Kintara and TuHURA entered into definitive merger agreement (the "Merger Agreement"), pursuant to which Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary (the "Merger"). The Merger is expected to close in the third quarter of 2024.

Kintara's existing stockholders will own approximately 5.5% of combined company's common stock at the closing of the Merger, inclusive of the contingent value right ("CVR") linked to the achievement of enrollment of a minimum of 10 patients in the REM-001 study, with such patients each completing 8 weeks of follow-up on or before December 31, 2025. TuHURA to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda®? in first-line treatment for advanced Merkel cell carcinoma in the second half of 2024 under FDA's accelerated approval pathway.

TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represent potential upside partnering opportunities. $31 million subscribed financing by TuHURA in connection with the Merger Agreement expected to provide cash runway into late 2025. On June 12, 2024, Kintara received a 180-day extension until December 9, 2024 from The Nasdaq Stock Market LLC to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).

Fourth Quarter 2024: Complete enrollment and 8 week follow-up of 10 patients in the REM the REM-001 study. 2H 2024: Commence TuHURA's Phase 3 trial forIFx- 2.0 personalised cancer vaccine for advanced Merkel cell carcinoma under FDA's accelerated approval pathway".